Semma raises $114 million for diabetes project

Semma Therapeutics Inc, a company founded by the Harvard University Professor Douglas Melton, has raised $114 million in an oversubscribed Series B financing round to bring a stem cell therapy for Type1 diabetes into the clinic.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United States